179 related articles for article (PubMed ID: 38192407)
1. Safety and risks of CBD oils purchased online: unveiling uncertain quality and vague health claims.
Vida RG; Strauss LV; Bajtel Á; Kiss T; Csupor D; Fittler A
Front Pharmacol; 2023; 14():1273540. PubMed ID: 38192407
[No Abstract] [Full Text] [Related]
2. Analysis of cannabidiol (CBD) and THC in nonprescription consumer products: Implications for patients and practitioners.
Miller OS; Elder EJ; Jones KJ; Gidal BE
Epilepsy Behav; 2022 Feb; 127():108514. PubMed ID: 34998268
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoid Content and Label Accuracy of Hemp-Derived Topical Products Available Online and at National Retail Stores.
Spindle TR; Sholler DJ; Cone EJ; Murphy TP; ElSohly M; Winecker RE; Flegel RR; Bonn-Miller MO; Vandrey R
JAMA Netw Open; 2022 Jul; 5(7):e2223019. PubMed ID: 35857320
[TBL] [Abstract][Full Text] [Related]
4. Selling cannabidiol products in Canada: A framing analysis of advertising claims by online retailers.
Zenone MA; Snyder J; Crooks V
BMC Public Health; 2021 Jul; 21(1):1285. PubMed ID: 34210299
[TBL] [Abstract][Full Text] [Related]
5. CBD Retailers in NC Promote CBD Online to Treat Pain Violating FDA Rules About Medical Claims and Offer Low-CBD/High-Price Products.
Amann L; Kruse E; Lazard AJ; Reboussin BA; Wagoner KG; Romero-Sandoval EA
J Pain Res; 2022; 15():3847-3858. PubMed ID: 36514481
[TBL] [Abstract][Full Text] [Related]
6. An assessment of qualitative and quantitative cannabinoids analysis in selected commercially available cannabis oils in Argentina.
Fernández N; Cappello MG; Quiroga PN
Forensic Sci Int; 2023 Aug; 349():111762. PubMed ID: 37392612
[TBL] [Abstract][Full Text] [Related]
7. Usage and health perception of cannabidiol-containing products among the population in Germany: a descriptive study conducted in 2020 and 2021.
Geppert J; Lietzow J; Hessel-Pras S; Kirsch F; Schäfer B; Sachse B
BMC Public Health; 2023 Nov; 23(1):2318. PubMed ID: 37996800
[TBL] [Abstract][Full Text] [Related]
8. Health Claims About Cannabidiol Products: A Retrospective Analysis of U.S. Food and Drug Administration Warning Letters from 2015 to 2019.
Wagoner KG; Lazard AJ; Romero-Sandoval EA; Reboussin BA
Cannabis Cannabinoid Res; 2021 Dec; 6(6):559-563. PubMed ID: 34142863
[No Abstract] [Full Text] [Related]
9. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
Theriaca; 2016; (43):9-61. PubMed ID: 27491172
[TBL] [Abstract][Full Text] [Related]
10. Content versus Label Claims in Cannabidiol (CBD)-Containing Products Obtained from Commercial Outlets in the State of Mississippi.
Gurley BJ; Murphy TP; Gul W; Walker LA; ElSohly M
J Diet Suppl; 2020; 17(5):599-607. PubMed ID: 32431186
[TBL] [Abstract][Full Text] [Related]
11. A comparison of advertised versus actual cannabidiol (CBD) content of oils, aqueous tinctures, e-liquids and drinks purchased in the UK.
Johnson DA; Hogan M; Marriot R; Heaney LM; Bailey SJ; Clifford T; James LJ
J Cannabis Res; 2023 Jul; 5(1):28. PubMed ID: 37438849
[TBL] [Abstract][Full Text] [Related]
12. A reliable and validated LC-MS/MS method for the simultaneous quantification of 4 cannabinoids in 40 consumer products.
Meng Q; Buchanan B; Zuccolo J; Poulin MM; Gabriele J; Baranowski DC
PLoS One; 2018; 13(5):e0196396. PubMed ID: 29718956
[TBL] [Abstract][Full Text] [Related]
13. Label accuracy of unregulated cannabidiol (CBD) products: measured concentration vs. label claim.
Johnson E; Kilgore M; Babalonis S
J Cannabis Res; 2022 Jun; 4(1):28. PubMed ID: 35658956
[TBL] [Abstract][Full Text] [Related]
14. Cannabinoid, Terpene, and Heavy Metal Analysis of 29 Over-the-Counter Commercial Veterinary Hemp Supplements.
Wakshlag JJ; Cital S; Eaton SJ; Prussin R; Hudalla C
Vet Med (Auckl); 2020; 11():45-55. PubMed ID: 32346530
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Claims in Cannabidiol (CBD) Marketing Messages on Twitter.
Soleymanpour M; Saderholm S; Kavuluru R
Proceedings (IEEE Int Conf Bioinformatics Biomed); 2021 Dec; 2021():3083-3088. PubMed ID: 35096472
[TBL] [Abstract][Full Text] [Related]
16. Knowledge of Tetrahydrocannabinol and Cannabidiol Levels Among Cannabis Consumers in the United States and Canada.
Hammond D; Goodman S
Cannabis Cannabinoid Res; 2022 Jun; 7(3):345-354. PubMed ID: 33998866
[No Abstract] [Full Text] [Related]
17. Cannabidiol (CBD) product contamination: Quantitative analysis of Δ
Johnson E; Kilgore M; Babalonis S
Drug Alcohol Depend; 2022 Aug; 237():109522. PubMed ID: 35690015
[TBL] [Abstract][Full Text] [Related]
18. Benefits, toxicity and current market of cannabidiol in edibles.
Astray G; Mejuto JC; Xiao J; Simal-Gandara J
Crit Rev Food Sci Nutr; 2023; 63(22):5800-5812. PubMed ID: 34989307
[TBL] [Abstract][Full Text] [Related]
19. Labeling of Cannabidiol Products: A Public Health Perspective.
Corroon J; MacKay D; Dolphin W
Cannabis Cannabinoid Res; 2020; 5(4):274-278. PubMed ID: 33381640
[No Abstract] [Full Text] [Related]
20. Product labeling accuracy and contamination analysis of commercially available cannabidiol product samples.
Gidal BE; Vandrey R; Wallin C; Callan S; Sutton A; Saurer TB; Triemstra JL
Front Pharmacol; 2024; 15():1335441. PubMed ID: 38562466
[No Abstract] [Full Text] [Related]
[Next] [New Search]
